Literature DB >> 12661044

IgG from patients with Guillain-Barré syndrome interact with nicotinic acetylcholine receptor channels.

K Krampfl1, B Mohammadi, B Buchwald, K Jahn, R Dengler, K V Toyka, J Bufler.   

Abstract

In Guillain-Barré syndrome (GBS), immunoglobulin G (IgG) antibodies block neuromuscular transmission pre- and postsynaptically and thus are of potential pathogenic relevance. We investigated whether IgG from GBS patients has a direct interaction with nicotinic acetylcholine receptor (nAChR) channels. Purified IgG fractions from six GBS patients that blocked neuromuscular transmission in a previous study were analyzed by the patch-clamp technique in combination with an ultrafast system for solution exchange. Sera from three patients with other inflammatory neurological disorders were used as controls. Mouse myotubes expressing native embryonic-type nAChR channels and human embryonic kidney (HEK) 293 cells transiently transfected with recombinant adult-type nAChR channels were used. Repeated 20-ms pulses of acetylcholine (ACh) were applied to outside-out patches in the presence of GBS-IgG. IgG of the patients had a significant reversible blocking action on embryonic- and adult-type nAChR channels with some variability in the magnitude of the block. Activation and desensitization kinetics were not affected when GBS-IgG was applied. None of the control sera blocked the AChR channels. The observed postsynaptic block effect fulfills the criteria of a channel-blocking IgG antibody similar to those seen in autoimmune myasthenia and may contribute to muscle weakness during the acute phase of GBS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12661044     DOI: 10.1002/mus.10349

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

1.  Temporal coincidence between AMAN type of GBS and myasthenia gravis.

Authors:  Jörg Kraus; Inga Teismann; Christoph Kellinghaus; Thomas Duning; E Bernd Ringelstein; Darius G Nabavi; Wolf-Rüdiger Schäbitz
Journal:  J Neurol       Date:  2007-02-17       Impact factor: 4.849

2.  Anti-ganglioside antibodies alter presynaptic release and calcium influx.

Authors:  Brigitte Buchwald; Gang Zhang; Angela K Vogt-Eisele; Weiyi Zhang; Raheleh Ahangari; John W Griffin; Hanns Hatt; Klaus V Toyka; Kazim A Sheikh
Journal:  Neurobiol Dis       Date:  2007-07-14       Impact factor: 5.996

Review 3.  Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction.

Authors:  Jaap J Plomp; Hugh J Willison
Journal:  J Physiol       Date:  2009-06-29       Impact factor: 5.182

Review 4.  [The significance of intravenous immunoglobulin in treatment of immune-mediated polyneuropathies].

Authors:  M Stangel; H-P Hartung; R Gold; B C Kieseier
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

5.  Simultaneous Combined Myositis, Inflammatory Polyneuropathy, and Overlap Myasthenic Syndrome.

Authors:  Stéphane Mathis; Laurent Magy; Philippe Corcia; Karima Ghorab; Laurence Richard; Jonathan Ciron; Mathilde Duchesne; Jean-Michel Vallat
Journal:  Case Rep Neurol Med       Date:  2016-12-01

6.  Clinical characteristics and outcomes of patients with overlapping Miller Fisher syndrome and myasthenia gravis.

Authors:  Jun-Liang Yuan; Yan Xing; Wen-Li Hu
Journal:  Arch Med Sci       Date:  2019-12-31       Impact factor: 3.318

Review 7.  Guillain-Barré syndrome associated with myasthenia gravis: Three cases report and a literature review.

Authors:  Yayun Cao; Mengcui Gui; Suqiong Ji; Bitao Bu
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

Review 8.  Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system.

Authors:  Nese Sinmaz; Tina Nguyen; Fiona Tea; Russell C Dale; Fabienne Brilot
Journal:  J Neuroinflammation       Date:  2016-08-30       Impact factor: 8.322

Review 9.  The clinical features of patients concurrent with Guillain-Barre syndrome and myasthenia gravis.

Authors:  Junliang Yuan; Juan Zhang; Bingwei Zhang; Wenli Hu
Journal:  Neurosciences (Riyadh)       Date:  2018-01       Impact factor: 0.906

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.